Jerome E Seid, MD | |
19229 Mack Ave Ste 24, Grosse Pointe Woods, MI 48236-2857 | |
(313) 884-5522 | |
(313) 884-5521 |
Full Name | Jerome E Seid |
---|---|
Gender | Male |
Speciality | Hematology/oncology |
Experience | 37 Years |
Location | 19229 Mack Ave Ste 24, Grosse Pointe Woods, Michigan |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407860364 | NPI | - | NPPES |
4231200 | Medicaid | MI | |
4234966 | Medicaid | MI | |
0828767 | Other | MI | BCN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RH0003X | Internal Medicine - Hematology & Oncology | JS056352 (Michigan) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Ascension St John Hospital | Detroit, MI | Hospital |
Ascension Macomb Oakland Hosp-warren Campus | Warren, MI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Ascension St John Hospital | 3173424082 | 296 |
News Archive
Nautic Partners, LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has completed a recapitalization of Healthcare Payment Specialists, LLC ("HPS") in partnership with management. HPS is a provider of payment and reimbursement solutions to hospitals and other healthcare systems.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.
The chairman of the Partnership to Improve Patient Care, Tony Coelho, encouraged racial and ethnic minority Americans to get more involved in comparative effectiveness research studies as a way to ensure that African Americans and other people of color have access to the latest treatment options and research available.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
Transplanting previously frozen ovarian tissue back into female cancer survivors can lead to long-term hormonal function and preservation of fertility, according to a new study by Samuel Kim from the University of Kansas Medical Center in the US. His work-, which shows that hormonal function was restored in five women 12-20 weeks after transplantation, and in one case lasted for more than seven years, appears online in the Journal of Assisted Reproduction and Genetics-, published by Springer.
› Verified 6 days ago
Entity Name | Ascension St John Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1043478910 PECOS PAC ID: 3173424082 Enrollment ID: O20040115000409 |
News Archive
Nautic Partners, LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has completed a recapitalization of Healthcare Payment Specialists, LLC ("HPS") in partnership with management. HPS is a provider of payment and reimbursement solutions to hospitals and other healthcare systems.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.
The chairman of the Partnership to Improve Patient Care, Tony Coelho, encouraged racial and ethnic minority Americans to get more involved in comparative effectiveness research studies as a way to ensure that African Americans and other people of color have access to the latest treatment options and research available.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
Transplanting previously frozen ovarian tissue back into female cancer survivors can lead to long-term hormonal function and preservation of fertility, according to a new study by Samuel Kim from the University of Kansas Medical Center in the US. His work-, which shows that hormonal function was restored in five women 12-20 weeks after transplantation, and in one case lasted for more than seven years, appears online in the Journal of Assisted Reproduction and Genetics-, published by Springer.
› Verified 6 days ago
Entity Name | Ascension Medical Group Michigan |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1114133485 PECOS PAC ID: 0648180406 Enrollment ID: O20081015000289 |
News Archive
Nautic Partners, LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has completed a recapitalization of Healthcare Payment Specialists, LLC ("HPS") in partnership with management. HPS is a provider of payment and reimbursement solutions to hospitals and other healthcare systems.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.
The chairman of the Partnership to Improve Patient Care, Tony Coelho, encouraged racial and ethnic minority Americans to get more involved in comparative effectiveness research studies as a way to ensure that African Americans and other people of color have access to the latest treatment options and research available.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
Transplanting previously frozen ovarian tissue back into female cancer survivors can lead to long-term hormonal function and preservation of fertility, according to a new study by Samuel Kim from the University of Kansas Medical Center in the US. His work-, which shows that hormonal function was restored in five women 12-20 weeks after transplantation, and in one case lasted for more than seven years, appears online in the Journal of Assisted Reproduction and Genetics-, published by Springer.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Jerome E Seid, MD 19229 Mack Ave Ste 24, Grosse Pointe Woods, MI 48236-2857 Ph: (313) 884-5522 | Jerome E Seid, MD 19229 Mack Ave Ste 24, Grosse Pointe Woods, MI 48236-2857 Ph: (313) 884-5522 |
News Archive
Nautic Partners, LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has completed a recapitalization of Healthcare Payment Specialists, LLC ("HPS") in partnership with management. HPS is a provider of payment and reimbursement solutions to hospitals and other healthcare systems.
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.
The chairman of the Partnership to Improve Patient Care, Tony Coelho, encouraged racial and ethnic minority Americans to get more involved in comparative effectiveness research studies as a way to ensure that African Americans and other people of color have access to the latest treatment options and research available.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to Silenor® (doxepin) under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
Transplanting previously frozen ovarian tissue back into female cancer survivors can lead to long-term hormonal function and preservation of fertility, according to a new study by Samuel Kim from the University of Kansas Medical Center in the US. His work-, which shows that hormonal function was restored in five women 12-20 weeks after transplantation, and in one case lasted for more than seven years, appears online in the Journal of Assisted Reproduction and Genetics-, published by Springer.
› Verified 6 days ago
Carrie L Dul, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 19229 Mack Ave Ste 24, Grosse Pointe Woods, MI 48236 Phone: 313-884-5522 Fax: 313-884-5521 | |
Mamta Sharma, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 19251 Mack Ave, Grosse Pointe Woods, MI 48236 Phone: 313-343-7280 Fax: 313-343-7921 | |
Ayad M. Al-katib, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 19229 Mack Ave, Suite 34, Grosse Pointe Woods, MI 48236 Phone: 313-647-3245 Fax: 313-647-3244 | |
Dr. Ashish Bhargava, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 19251 Mack Ave Ste 333, Grosse Pointe Woods, MI 48236 Phone: 313-343-7280 Fax: 313-343-7921 | |
Dr. Ronald D Hertz, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 19251 Mack Ave, Grosse Pointe Woods, MI 48236 Phone: 313-343-3749 Fax: 313-343-7921 | |
Thomas Joseph Loss, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 19299 Mack Ave Ste 34, Grosse Pointe Woods, MI 48236 Phone: 313-647-3245 Fax: 313-647-3244 | |
Zyad Kafri, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 19229 Mack Ave, Suite 23, Grosse Pointe Woods, MI 48236 Phone: 313-647-3245 Fax: 313-647-3244 |